In preclinical models, ETV6-NTRK3 has been shown to promote the development of an aggressive B-ALL and to be exquisitely sensitive to the TRK inhibitors larotrectinib (LOXO-101) or PLX7486 (Plexxikon) in both patient derived xenograft models and in B-ALL patients with ETV6-NTRK3 [55,59,60]. Here, ETV6 is linked to precursor B-cell acute lymphoblastic leukemia.